KBC Group
KYMR icon

KBC Group’s Kymera Therapeutics KYMR Stock Holding History

KBC Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$143K Hold
1,716
– – ﹤0.01% 1116
2025
Q4 		$134K Hold
1,716
– – ﹤0.01% 1109
2025
Q3 		$97K Hold
1,716
– – ﹤0.01% 1279
2025
Q2 		$75K Sell
1,716
-763
-31% -$26.3K ﹤0.01% 1391
2025
Q1 		$68K Buy
2,479
+328
+15% +$12K ﹤0.01% 1692
2024
Q4 		$87K Buy
2,151
+752
+54% +$34K ﹤0.01% 1638
2024
Q3 		$66K Hold
1,399
– – ﹤0.01% 1563
2024
Q2 		$42K Hold
1,399
– – ﹤0.01% 1710
2024
Q1 		$56K Buy
+1,399
New +$50.1K ﹤0.01% 1486

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

KBC Group's KYMR Position: Q1 2026 in Review

KBC Group held its Kymera Therapeutics (KYMR) position steady in Q1 2026 at 1,716 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #1116.

KBC Group first reported a position in KYMR in Q1 2024 and has held it in 9 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • KBC Group held 1,716 shares of Kymera Therapeutics worth $143K as of Q1 2026.
  • KBC Group left its Kymera Therapeutics share count unchanged in Q1 2026.
  • Kymera Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1116 holding.
  • KBC Group first reported a position in Kymera Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.